Could the CSL share price be set for a boost before the year's end?

The CSL share price has been sluggish all year. Could a new drug treatment for haemophilia B turn things around?

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have been sluggish all year and are down again today 
  • The company is developing a gene therapy to treat haemophilia B
  • The treatment is in Phase III and could be released to the market before the year is out if it gets approval from the US Food and Drug Administration

The CSL Limited (ASX: CSL) share price is in the red today, down 0.42% at the time of writing to $281.83.

CSL shares have been sluggish in recent times, down 5.1% in the past month and down 5.2% overall in 2022.

The company hasn't announced any price-sensitive news since its FY22 results on 17 August. But there have been some good developments in the CSL lab of late, as reported by The Age today.

New drug could boost earnings

EtranaDez is a gene therapy that CSL is developing to treat haemophilia B.

Patients with haemophilia B don't have the blood clotting protein Factor-IX. According to the article, EtranaDez instructs the patient's cells to produce Factor-IX, thereby negating the need for regular and time-consuming intravenous treatments.

The drug is currently in Phase III of its development. According to the article, the US Food and Drug Administration is expected to decide whether to approve the drug later this year.

CEO Paul Perreault hopes to put EtranaDez into the market before the year is out.

Whether this could boost the CSL share price remains to be seen.

What do the experts think?

The Institute for Clinical and Economic Review (ICER) has just published a draft report on the potential financial benefits of EtranaDez for CSL.

The ICER assumes a "placeholder price" of $2.5 million in the United States market.

In a note to clients, Wilsons analyst Dr Shane Story said the report "frames the potential benefit of a one-time prophylactic injection which could stabilise the [haemophilia B] for years".

The Wilsons equities team says the drug will enhance CSL's existing haemophilia treatments. It expects "at least 10 per cent in incremental share from the currently underserved young adult patient segment".

Macquarie and Credit Suisse analysts think EtranaDez will benefit CSL's earnings pipeline into 2024.

In a note to clients, Credit Suisse said it forecasts "peak sales of $US400 million with $US200 million upside to CSL's FY34 earnings".

CSL began developing the drug in a $655 million partnership with the NASDAQ-listed genomic medicine company UniQure in 2020.

A quick history on the CSL share price

Before the pandemic hit the ASX, the CSL share price was as high as $336.40 in February 2020. It came crashing down with the rest of the market to an initial low of $270.88 in March 2020.

Since then, CSL shares have been rangebound between the mid-$200s and about $315.

The CSL share price has not risen above $300 since December 2021.

Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »

Health professional putting on gloves.
Healthcare Shares

How will Ansell shares navigate tariffs according to Macquarie?

The next two years could be a challenging period for the PPE company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is surging 18% on big news

This stock is getting a lot of love from investors on Monday.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Healthcare Shares

CSL shares are having a tough time recently. Are they a buy or a sell?

Is now a good time to jump in and buy this blue chip star?

Read more »